placeholder
Importance
62
Trust
71
Urgency
30
CLINICAL TRIAL
Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial - Yahoo Finance
Novo Nordisk is testing semaglutide (a weight-loss drug) in people with alcohol problems and running a trial of LX9851 (a new drug similar to semaglutide). Both studies show the company is exploring new uses for its peptide medicines.
Analysis
Novo is looking for new ways to use semaglutide beyond weight loss. New uses could mean more sales and a stronger drug pipeline.
- Novo Nordisk is testing semaglutide in people with alcohol problems
- Novo Nordisk is running a trial of a new drug called LX9851
Novo Nordisk News1mo
Read